Global Hemoglobinopathies Market Size to Worth USD 19.45 Billion by 2032
According to a research report published by Spherical Insights & Consulting, The Global Hemoglobinopathies Market size is to grow from USD 7.85 billion in 2022 to USD 19.45 billion by 2032, at a Compound Annual Growth Rate (CAGR) of 9.5% during the forecast period.
Get more details on this report -
Browse key industry insights spread across 200 pages with 100 market data tables and figures & charts from the report on "Global Hemoglobinopathies Market Size, Share, and COVID-19 Impact Analysis, By Indication Type (Sickle Cell Disease, Alpha Thalassemia, and Beta Thalassemia), By Test Type (Red blood cell (RBC) count test, Genetic testing, hemoglobin by high-performance liquid chromatography (HPLC) test, Hemoglobin isoelectric (Hb IEF) focusing, Hemoglobin electrophoresis (Hb ELP) test, and Hemoglobin solubility test), By End-User (Hospitals, Diagnostic Laboratories, and Clinics), By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2023 – 2032." Get Detailed Report Description Here: https://www.sphericalinsights.com/reports/hemoglobinopathies-market
Hemoglobinopathies are a group of genetic disorders characterized by abnormalities in the structure or production of hemoglobin, the protein responsible for transporting oxygen in red blood cells. The most common and well-known hemoglobinopathy is sickle cell disease, where a mutation in the HBB gene results in the formation of abnormal, crescent-shaped red blood cells that can cause vaso-occlusive crises, anemia, and various complications. Thalassemias, another group of hemoglobinopathies, involves reduced production of either the alpha or beta globin chains, leading to an imbalance in hemoglobin subunits and subsequent anemia. Hemoglobinopathies predominantly affect populations in regions where malaria is endemic, as the genetic variations can provide some resistance to the disease.
In 2022, the sickle cell disease segment accounted for around 42.5% market share
On the basis of the indication type, the global hemoglobinopathies market is segmented into sickle cell disease, alpha thalassemia, and beta thalassemia. The sickle cell disease segment has secured the largest market share in the hemoglobinopathies market due to its high prevalence and significant disease burden, particularly in regions like Sub-Saharan Africa and certain parts of North America. This segment has attracted substantial research investments and pharmaceutical developments, leading to a broader range of therapeutic options. Additionally, the growing recognition of sickle cell disease as a global health concern has prompted increased funding, awareness, and advocacy efforts, further propelling its prominence within the hemoglobinopathies market.
The red blood cell count test segment held the largest market with more than 32.8% revenue share in 2022
Based on the test type, the global hemoglobinopathies market is segmented into red blood cell count test, genetic testing, hemoglobin by high-performance liquid chromatography test, hemoglobin isoelectric focusing, hemoglobin electrophoresis test, and hemoglobin solubility test. The red blood cell count test segment has claimed the largest market share in the hemoglobinopathies diagnostic market due to its fundamental role in assessing and diagnosing various blood disorders, including hemoglobinopathies. It serves as a key initial screening tool for healthcare providers to detect abnormalities in red blood cell count, shape, and hemoglobin content, which are critical indicators of these conditions.
The diagnostic laboratories segment held the largest market with more than 45.2% revenue share in 2022
Based on the end-user, the global hemoglobinopathies market is segmented into hospitals, diagnostic laboratories, and clinics. The diagnostic laboratories segment has emerged as the dominant player in the hemoglobinopathies diagnostic market due to its pivotal role in offering comprehensive and precise diagnostic services. These specialized laboratories possess state-of-the-art equipment and highly trained personnel, enabling them to conduct a wide range of tests and analyses, including genetic testing and hemoglobin electrophoresis. As hemoglobinopathies often require complex and specialized diagnostics for accurate identification and classification, diagnostic laboratories provide essential services, making them the primary choice for healthcare providers and patients, thus contributing to their largest market share
Asia-Pacific is predicted to grow at a fastest CAGR of around 9.7% over the projected period
Get more details on this report -
Based on region, the Asia-Pacific region is projected for the fastest growth in the hemoglobinopathies market due to several key factors, such as rising population numbers, particularly in countries like India and China, contributing to a substantial patient pool. Additionally, improving healthcare infrastructure, increasing awareness, and expanding access to advanced diagnostics and treatments are driving market growth. Moreover, Asia Pacific's growing biotechnology and pharmaceutical industry, coupled with government initiatives to address rare diseases, are fostering research and development efforts, creating a conducive environment for rapid market expansion in the coming years.
North America's dominant revenue share in the hemoglobinopathies market can be attributed to advanced healthcare infrastructure, high healthcare expenditure, and a strong focus on research and development. Additionally, North America has a relatively large population with diverse ethnic backgrounds, including populations with a higher prevalence of hemoglobinopathies such as sickle cell disease.
Some of the major players in the global hemoglobinopathies market include Sangamo Therapeutics, Inc., Global Blood Therapeutics, Inc., Bluebird Bio, Inc., Emmaus Life Sciences Inc., Pfizer, Inc., Novartis AG, Prolong Pharmaceuticals, LLC, Bioverativ Inc., Gamida Cell, and Celgene Corporation.
This study forecasts revenue at global, regional, and country levels from 2019 to 2032. Spherical Insights has segmented the global hemoglobinopathies market based on the below-mentioned segments:
Hemoglobinopathies Market, By Indication Type
- Sickle Cell Disease
- Alpha Thalassemia
- Beta Thalassemia
Hemoglobinopathies Market, By Test Type
- Red blood cell (RBC) count test
- Genetic testing, hemoglobin by high-performance liquid chromatography (HPLC) test
- Hemoglobin isoelectric (Hb IEF) focusing
- Hemoglobin electrophoresis (Hb ELP) test
- Hemoglobin solubility test
Hemoglobinopathies Market, By End-User
- Diagnostic Laboratories
Hemoglobinopathies Market, Regional Analysis
- North America
- Rest of Europe
- Asia Pacific
- South Korea
- Rest of Asia Pacific
- South America
- Rest of South America
- Middle East & Africa
- Saudi Arabia
- South Africa
- Rest of Middle East & Africa
About the Spherical Insights & Consulting
Spherical Insights & Consulting is a market research and consulting firm which provides actionable market research study, quantitative forecasting and trends analysis provides forward-looking insight especially designed for decision makers and aids ROI.
Which is catering to different industry such as financial sectors, industrial sectors, government organizations, universities, non-profits and corporations. The company's mission is to work with businesses to achieve business objectives and maintain strategic improvements.
For More Information on Your Target Market, Please Contact Us Below:
Phone: +1 303 800 4326 (the U.S.)
Phone: +91 90289 24100 (APAC)
Contact Us: https://www.sphericalinsights.com/contact-us
Need help to buy this report?